Abstract
A 42-year-old woman had acromegaly and a large macroadenoma with supra- and parasellar extension. Her GH levels (median 85 ng/ml, range 63–170 ng/ml) were not responsive to TRH (200 μg iv), GHRH (100 μg iv) and bromocriptine (Br 2.5 mg po) acute tests; Sm-C level was 8 U/ml. She was treated with octreotide (SMS) (up to 1500 μg daily) for 3 months. No changes of clinical, biochemical and radiological findings were seen, therefore she underwent transsphenoidal surgery. After surgery, hypopituitarism and diabetes insipidus appeared: GH levels remained high (median 45 ng/ml; range 37–56 ng/ml), but became responsive to Br acute test. The patient was given SMS again, and this resulted in clinical improvement, marked reduction of GH and Sm-C levels and slight shrinkage of the residual tumor. Speculative hypotheses about this previously unreported phenomenon might be either an excess of both GHRH and somatostatin, caused by a primary increase of dopaminergic tone, or a primary excess only of GHRH; in both cases the surgical lesion of the hypothalamic-pituitary region might have impaired the neurohormones inflow to the residual pituitary and so let SMS and Br exert their inhibitory actions on GH secretion.
Similar content being viewed by others
References
Lamberts S.W.J. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr. Rev. 9:417, 1988.
Cozzi R., Chiodini P.G., Boccardi E., Dallabonzana D., Oppizzi G., De Palo C., Piolini M., Liuzzi A. Antitumoral effect of the long-term treatment of acromegaly with Sandostatin. 70th Ann. Meet. Endocr. Soc., New Orleans, USA, 1988, Abstract 114.
Reubi J.C., Landolt A.M. The growth hormone response to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J. Clin. Endocrinol. Metab. 68: 844, 1989.
Chiodini P.G., Liuzzi A., Dallabonzana D., Oppizzi G., Verde G. Changes in growth hormone (GH) secretion induced by human pancreatic GH-releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine. J. Clin. Endocrinol. Metab. 60: 48, 1985.
Kitajima N., Chihara K., Abe H., Okimura Y., Fujii Y., Sato M., Shakutsui S., Waranabe M., Fujita T. Effects of dopamine on immunoreactive growth hormone-releasing factor and somatostatin secretion from rat hypothalamic slices perfused in vitro. Endocrinology 124: 69, 1989.
Di Paolo T., Falardeau P. Dopamine receptors in rat pituitary and estradiol-induced pituitary tumors: effect of chronic treatment with bromocriptine. Biochem. Biophys. Res. Commun. 123: 312, 1984.
Heisler S., Srikant C.B. Somatostatin-14 and Somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3′-5′-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. Endocrinology 117: 217, 1985.
Presky D.H., Schonbrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J. Biol. Chem. 263: 714, 1988.
Reubi J.C., Heitz P.U., Landolt A.M. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J. Clin. Endocrinol. Metab. 65: 65, 1987.
Kelijman M., Williams T.C., Downs T.R., Frohman L.A. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. J. Clin. Endocrinol. Metab. 67: 958, 1988.
Wilson D.M., Hoffman A.R. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumor secreting growth hormone releasing factor. Acta. Endocrinol. (Copenh.) 113: 23, 1986.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Attanasio, R., Chiodini, P.G., Liuzzi, A. et al. Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly. J Endocrinol Invest 13, 683–687 (1990). https://doi.org/10.1007/BF03349598
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349598